US5411947A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
Assignee: HOSTETLER FAMILY TRUST
•
Filing: 1992-12-16
•
Granted: 1995-05-02
•
Expires: 2012-12-16
Abstract
Abstract The oral delivery of many classes of drugs is facilitated by converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives. The method confers the ability to be absorbed through the digestive tract to drugs that are not orally bioavailable in the non-derivatized state, and enhances the effectiveness of drugs that are poorly absorbed or rapidly eliminated. The method provides orally bioavailable lipid prodrugs of pharmaceutical compounds having diverse physiological activities, including anticancer and antiviral agents, anti-inflammatory agents, antihypertensives and antibiotics. Potency of the lipid prodrugs is comparable to that of the corresponding non-derivatized drugs.
Inventors
- 👤 Karl Y. Hostetler
- 👤 Raj Kumar
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 20:40
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/02; C07H15/04; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/54; A61K47/542; A61K47/543; A61K47/544; A61K47/548; A61K9/00; A61K9/10; A61K9/127; A61P; A61P35/00; B; B82; B82Y; B82Y5/00; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3886; C07F9/3891; C07F9/40; C07F9/4003; C07F9/4006; C07F9/4062; C07F9/4065; C07F9/547; C07F9/655; C07F9/6551; C07F9/65512; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/16
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
106 words
A method of converting a drug that is unavailable or poorly available in a mammal through the oral route of administration to an orally available form, comprising: (a) covalently linking a lipid species selected from the group consisting of 1-O-alkyl-sn-glycerol-3-phosphates, and 1-O-acyl-sn-glycerol-3-phosphates to a functional group of said drug either directly through the phosphate group of the lipid species or through a multifunctional linker molecule to form a lipid derivative of the drug; (b) recovering the lipid derivative of the drug from the linking reaction mixture of step (a); and (c) incorporating the lipid derivative of the drug into a therapeutic formulation suitable for oral administration.
Claim 2
Independent Claim
106 words
A method of converting a drug that is unavailable or poorly available in a mammal through the oral route of administration to an orally available form, comprising: (a) covalently linking a lipid species selected from the group consisting of 1-O-alkyl-sn-glycerol-3-phosphates, and 1-O-acyl-sn-glycerol-3-phosphates to a functional group of said drug either directly through the phosphate group of the lipid species or through a multifunctional linker molecule to form a lipid derivative of the drug; (b) recovering the lipid derivative of the drug from the linking reaction mixture of step (a); and (c) incorporating the lipid derivative of the drug into a therapeutic formulation suitable for oral administration.
Claim 3
Dependent Claim
111 words
The method of claim 1 wherein said lipid derivative is a 1-O-alkyl-sn-glycerol-3-phosphate derivative of a drug, of the formula ##STR4## wherein R is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain, or cyclic C 1-24 alkyl group, covalently linked to the glycerol moiety in an ether linkage; n=0 to 2; L is a linking molecule, of the formula X--(CH 2 ) n --Y wherein X and Y are functional groups independently selected from hydroxyl, sulfhydryl, carboxyl and amine groups, and n=1 to 24; or L is absent; and D is a drug having a functional group selected from the group consisting of hydroxyl, sulfhydryl, carboxyl, or amino groups.
Claim 4
Dependent Claim
23 words
The method of claim 2, wherein the drup is an anticancer nucleoside having a carboxyl, hydroxyl, or amino group available for covalent binding.
Claim 5
Dependent Claim
18 words
The method of claim 3, wherein the drug is 9-β-D-arabinofuranosylcytosine (ara-C), 5-fluorouridine, 6-mercaptopurine riboside, 9-β-D-arabinofuranosyladenine (ara-A), or 2'-arafluoro-2-chloro-deoxyadenosine.
Claim 6
Dependent Claim
13 words
The method of claim 2, wherein the drug is 5-amino-4-imidazole carboxamide ribonucleoside (AICA-riboside).
Claim 7
Dependent Claim
25 words
The method of claim 2, wherein D is a therapeutic peptide, or a peptidomimetic of from 3 to 35 amino acid residues or analogues thereof.
Claim 8
Dependent Claim
11 words
The method of claim 6, wherein the drug is n-muramyl tripeptide.
Claim 9
Dependent Claim
10 words
The method of claim 6, wherein the drug is enalkiren.
Claim 10
Dependent Claim
22 words
The method of claim 2, wherein the drug is selected from the group consisting of antibiotics of the penicillin and cephalosporin class.
Claim 11
Dependent Claim
21 words
The method of claim 9, wherein the drug is selected from the group consisting of penicillin G, cefazolin, ceftazidime, ceftriaxone, piperacillin.
Claim 12
Dependent Claim
11 words
The method of claim 1, wherein said drug is 3'-azido-3'-deoxythymidine (AZT).
Claim 13
Dependent Claim
11 words
The method of claim 1, wherein said drug is 3'-azido-3'-acycloguanosine (ACG).
References Cited (Backward Citations)
US4046914A
Cited
US4634719A
Cited
US4471113A
Cited
US5071839A
Cited
US5194654A
Cited
EP0457570A1
Cited
WO1991019726A1
Cited
WO1992019233A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-05-01 | 1998-10-31 | 1999-05-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-05-01 | 2002-10-31 | 2003-05-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-05-01 | 2006-10-31 | 2007-05-02 | $7700.00 | Window Closed / Lapsed |